Nutrition is required at every stage of fracture healing and these include adequate calories and protein, minerals and vitamins, and medications that promote blood supply are also beneficial for fractures. On the other hand, calcium and vitamin D, bone resorption inhibitors and bone formation-promoting agents are the main medications used to combat osteoporosis, and some of these medications are also beneficial for fracture healing. Long-term application of vitamin D drugs can promote intestinal calcium and phosphorus absorption, and the combined application of calcium and vitamin D drugs has a positive effect on fracture healing. Common bone resorption inhibitors include estrogens, estrogen receptor modulators, calcitonin and diphosphonates, which can inhibit the activity of osteoclasts or reduce the number of osteoclasts to varying degrees thereby reducing bone loss, and have a definite role in the treatment of osteoporosis, but fracture healing requires bone metabolism at the healing end and osteogenesis at the time of osteogenesis. Based on clinical observations, the role of estrogenic drugs, estrogen receptor modulators, and calcitonin in promoting fracture healing is more certain, while the role of diphosphonates in the fracture healing process is debated. Parathyroid hormone is the only drug used clinically to promote bone formation, and although its positive effect on fracture healing has been found in clinical studies, it remains to be studied in terms of safety and optimal dosage. Strontium ranelate, with its “dual action” of inhibiting bone resorption and promoting bone formation, is still being investigated for its effects on fracture healing, and current research suggests that it may be the drug of choice for fracture healing because of its unique mechanism of action and good therapeutic effects. In addition to their effects on fractures, these drugs also have effects on other systems of the body, and their effectiveness and safety need to be weighed when choosing to apply them.